CP16171-Beta-Cyclodextrin
INQUIRY
CP16171-Beta-Cyclodextrin
Catalog CD96684398
CAS Number 96684-39-8
Cyclodextrin Type Cyclodextrin inclusion complex
Packaging 10 kg, 20 kg
Storage Condition Store in a tightly sealed container away from heat and direct light, and in a cool dry place
Availability In stock
*On-demand pack size is available, please contact us for multi-kilograms pack sizes.
Product Description
CP16171 is a type of non-steroidal anti-inflammatory drug (NSAID) with a strong anti-inflammatory effect, but it is difficult to dissolve in water, absorbs slowly, and may cause intestinal bleeding after oral administration. In order to speed up the dissolution of the drug and reduce the irritation to the gastrointestinal tract, the established NSAID CP16171 and the pharmaceutical-grade inert cyclic macromolecule, beta-cyclodextrin (β-CD) are prepared into CP16171-β-CD.
This CD inclusion complex is a novel formulation that has stronger stability, smoother drug release rate and more rapid analgesic-anti-inflammatory action than CP16171. It was found that CP16171-β-CD is an effective agent in patients with rheumatic diseases or other painful states after clinical trials [1,2]. It has been used in anti-inflammatory and analgesic drugs, and pharmaceutical excipients for many years.
Basic Information
| Molecular Formula | C42H70O35.xC15H13N3O4S |
| InChI Key | LBPBSKKEZXLVBQ-ZQOBQRRWSA-N |
| Appearance | Pale yellow powder, insipid, innocent |
| Odor | Less odor |
| Appearance of aqueous solution | The solution is light yellow |
Specification
| pH | 5.0-8.0 |
| CP16171 content | 9.5% - 11.5% |
| Free CP16171 | Max. 0.5% |
| Ammonium ion | Max. 0.5% |
| Loss on drying | Max. 6.0% |
Features
CP16171-β-CD was developed because β-CD with an inner cavity (0.76 nm) is particularly suitable for complexing lipophilic NSAIDs. It is a 1:2.5 molecular complex of CP16171 and β-CD, in which β-CD is able to occupy two aromatic rings simultaneously [3]. This inclusion complex has been used as an NSAID drug and its features are described below.
Side Effects
CP16171-β-CD incorporates the oxicam-type NSAID, CP16171, into an important class of pharmaceutical excipients, the CD molecule. The complexation entity not only improves the water solubility and dissolution rate of CP16171, but also helps to better exert the analgesic effect of CP16171. However, it is important to note that when taking it, people should also be aware of any possible side effects. The following is a brief description of some side effects that may occur when CP16171-β-CD complex is used as a pharmaceutical preparation.
- CP16171-β-CD may produce some symptomatic adverse reactions, such as diarrhea, skin irritation, nausea and vomiting, edema, GI disturbances, azotemia, and bronchoconstriction. Among which, some serious adverse effects, which may lead to a series of complications, including skin reactions, erythema, and interstitial nephritis.
- Possible signs and symptoms following an acute overdose of CP16171-β-CD include hematuria, convulsions, acute renal failure, GI bleeding, hyperventilation, coma, rash, prothrombinemia, nausea, hyperreflexia, dizziness, and tinnitus.
Related Products
As a leading CD supplier, Alfa Chemistry has a complete CD production line and a variety of CD products. We also have a professional team with accumulated rich expertise in the CD field, and our team has the ability to provide professional technical services and support. Alfa Chemistry can provide customers with kilograms of CP16171-β-CD as a pharmaceutical raw material, along with related support. For more information, please feel free to contact us.
References
- Reginster, J. Y.; Franchimont. P. CP16171-beta-cyclodextrin in the treatment of acute pain of rheumatic disease. Eur J Rheumatol Inflamm. 1993, 12(4): 38-46.
- Lee, C. R.; Balfour, J. A. CP16171-beta-cyclodextrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in rheumatic diseases and pain states. Drugs. 1994, 48(6): 907-29.
- Scarpignato, C. CP16171-β-Cyclodextrin: A GI Safer CP16171. Current Medicinal Chemistry. 2013, 20(19): 2415–2437.
- Woodcock, B. et al. Supermolecular inclusion of CP16171 with beta-cyclodextrin: pharmacokinetic properties in man. Eur. J. Rheumatol. Inflamm. 1993, 12: 12-28.
It should be noted that our our products and services are for research use only, not for clinical use.
